Enanta Pharma (ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Enanta Pharma (NASDAQ: ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)